Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...
Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...
Eli Lilly (LLY) shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting ...
Eli Lilly saw a decline of 1.4% in its share price today, trading as low as $771.00. Trading volume was much lower than average, with 444,906 shares traded (an 86% decrease from the average ...
Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings at $5.08 per share, up from $2.49 per ...
Eli Lilly and Company LLY will report its fourth ... for sales and earnings is pegged at $13.72 billion and $5.15 per share, respectively. Earnings estimates for 2025 have declined from $24. ...
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a ...
The company's simple, shareholder- and customer-first ethos is delivering not only stellar revenue growth, but immense triple digit GAAP and non-GAAP earnings per share growth. There are other ...
Investing.com - Eli Lilly's (NYSE: LLY) full-year profit forecast largely surpassed Wall Street expectations on Thursday, as ...
Eli Lilly (LLY) is set to report fourth-quarter ... This article has been updated to reflect more recent analyst estimates and share price values. Investopedia requires writers to use primary ...
Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback